European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment

  title={European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment},
  author={Veit Roessner and Heike Eichele and Jeremy Stern and Liselotte Skov and Renata Rizzo and Nanette Mol Debes and Peter Nagy and Andrea Eugenio Cavanna and Cristiano Termine and Christos Ganos and Alexander M{\"u}nchau and Natalia Szejko and Danielle C. Cath and Kirsten R. M{\"u}ller-Vahl and Cara Verdellen and Andreas Hartmann and Aribert Rothenberger and Pieter J. Hoekstra and Kerstin Jessica Plessen},
  journal={European Child \& Adolescent Psychiatry},
  pages={425 - 441}
In 2011, the European Society for the Study of Tourette Syndrome (ESSTS) published the first European guidelines for Tourette Syndrome (TS). We now present an update of the part on pharmacological treatment, based on a review of new literature with special attention to other evidence-based guidelines, meta-analyses, and randomized double-blinded studies. Moreover, our revision took into consideration results of a recent survey on treatment preferences conducted among ESSTS experts. The first… 
Updated European guidelines for Tourette syndrome: and now use them!
This focused issue of European Child and Adolescent Psychiatry contains fully updated guidelines for the assessment and treatment of Tourette syndrome, written by European experts, and particularly disappointing were insufficient involvement of teachers and schools in the treatment process, limited implementation of psychoeducational methods, as well as a lack of careful examination of patients.
Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study
MC treatment demonstrates good efficacy and tolerability in adult GTS patients and Predilection for smoking rather than using oil drops requires further comparative studies to evaluate the efficacy of each.
Use of Nutritional Supplements Based on L-Theanine and Vitamin B6 in Children with Tourette Syndrome, with Anxiety Disorders: A Pilot Study
Background: Tourette syndrome (TS) is a neurodevelopmental disorder characterized by tics and co-occurring disorders. It has been suggested that anxiety occurs in 2–45% patients affected by Tourette
ONLINE-TICS: Internet-Delivered Behavioral Treatment for Patients with Chronic Tic Disorders
Although the primary endpoint was narrowly missed, it is strongly suggested that i CBIT is superior compared to placebo, and treatment effects of iCBIT even increased over time.
Neurology - to be or not to be of the cannabis-based medicine?
  • N. Szejko
  • Medicine, Psychology
    Neurologia i neurochirurgia polska
  • 2022
This edition of the Polish Journal of Neurology and Neurosurgery contains a Leading Topic dedicated to the use of cannabis-based medicine (CBM) in neurology, with four articles that tackle different aspects of CBM use and offer a wide overview, from general information to detailed aspects concerning a particular disease.
Efficacy of the Jingxin Zhidong Formula for Tic Disorders: A Randomized, Double Blind, Double Dummy, Parallel Controlled Trial
JXZDF had a better safety profile than aripiprazole, and it was not inferior in terms of clinical efficacy, and warrants consideration as a potential treatment option for TD.
Inhibitory Control in Children with Tourette Syndrome Is Impaired in Everyday Life but Intact during a Stop Signal Task
The results indicate that children with TS are not impaired in a laboratory-based measure of IC, although some difficulties were evident from measures of everyday behaviour, which may in part be due to parents and teachers interpreting tics as disinhibited behaviour.
Acute and Long-Term Effects of an Internet-Based, Self-Help Comprehensive Behavioral Intervention for Children and Teens with Tic Disorders with Comorbid Attention Deficit Hyperactivity Disorder, or Obsessive Compulsive Disorder: A Reanalysis of Data from a Randomized Controlled Trial
The effects of an internet-delivered, self-help comprehensive behavioral intervention for tics (ICBIT) in children and adolescents with TD with and without comorbid diagnoses of ADHD or OCD at post intervention and over three- and six-month follow-up periods are described.
A Randomized Controlled Trial Comparing Videoconference vs. Face-to-Face Delivery of Behavior Therapy for Youths With Tourette Syndrome in the Time of COVID-19
Online remote behavior therapy is a promising tool for behavioral therapies for patients with Tourette Syndrome and may represents an alternative treatment option.
NDT_A_347432 57..66
JXZDF had a better safety profile than aripiprazole, and it was not inferior in terms of clinical efficacy, and warrants consideration as a potential treatment option for TD.


European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment
A summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice is presented and is not a status quo of a clinically helpful but merely low evidence guideline.
European clinical guidelines for Tourette Syndrome and other tic disorders. Part III: behavioural and psychosocial interventions
This clinical guideline provides recommendations for the behavioural and psychosocial interventions (BPI) of children and adolescents with tic disorders prepared by a working group of the European
Trials of Pharmacological Interventions for Tourette Syndrome: A Systematic Review
The alpha-2 agonist Clonidine is amongst the agents with the most favourable efficacy-versus-adverse events ratio, especially in patients with co-morbid attention-deficit hyperactivity disorder, although effect sizes vary evidence-based studies.
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders
Evidence to support the efficacy of various medical, behavioral, and neurostimulation interventions for the treatment of tics is demonstrated and harms associated with interventions must be considered in making treatment recommendations.
The Role of Atypical Antipsychotics for Treatment of Tourette’s Syndrome: An Overview
An updated overview of the role of atypical antipsychotics for treatment of Tourette’s syndrome is provided, with evidence-based guidance on their use.
Clinical pharmacology of comorbid obsessive-compulsive disorder in Tourette syndrome.
Refractoriness to pharmacological treatment for tics: A multicentre European audit
Evidence-based treatment of Tourette’s disorder and chronic tic disorders
This expert review evaluated the empirical support for behavioral and pharmacological interventions based on the results of randomized controlled trials (RCTs) for Chronic Tic Disorders and Tourette’s Disorder.